Skip to main content
. 2021 Apr 8;24(4):1048–1054. doi: 10.1038/s41391-021-00343-2

Fig. 1. The cumulative incidence rates and reason of discontinuation of the first 500 patients included in the PRIAS study, long before the introduction of MRI with targeted biopsies (i.e. Group A).

Fig. 1

SBx systematic biopsies, GG Grade Group, PCa prostate cancer.